/ATYR
ATYR Stock - aTyr Pharma, Inc.
Healthcare|BiotechnologyNASDAQ
$0.75+6.67%
+$0.05 (+6.67%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.1
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.97
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+584.0%upside
Target: $5.13
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ATYR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.74 – $0.76
TARGET (TP)$5.13
STOP LOSS$0.69
RISK/REWARD1:73.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.58
52W High$7.29
52W Low$0.64
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $235,000 | $353,000 | $10.39M | N/A | $10.46M |
| Gross Profit | $235,000 | $353,000 | $8.69M | $-1,304,000 | $-6,836,000 |
| Gross Margin | 100.0% | 100.0% | 83.7% | N/A | -65.4% |
| Operating Income | $-67,914,000 | $-54,919,000 | $-46,404,000 | $-34,015,000 | $-15,911,000 |
| Net Income | $-64,023,000 | $-50,389,000 | $-45,338,000 | $-33,768,000 | $-16,224,000 |
| Net Margin | -27243.8% | -14274.5% | -436.5% | N/A | -155.2% |
| EPS | $-0.86 | $-0.94 | $-1.60 | $-1.77 | $-1.77 |
Company Overview
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
40%
Hold / Neutral
3
60%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
2 Bullish3 Neutral/Bearish
Price Targets
$8
Average Target
↑ 911.1% Upside
Now
$1
Low
$8
Average
$17
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 16th 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $1.5 |
| September 15th 2025 | Wells Fargo | Downgrade | Equal Weight | $1 |
| September 15th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| September 15th 2025 | Leerink Partners | Downgrade | Market Perform | $1 |
| September 15th 2025 | Cantor Fitzgerald | Downgrade | Neutral | - |
| February 18th 2025 | Leerink Partners | Initiation | Outperform | $16 |
| January 6th 2025 | Cantor Fitzgerald | Initiation | Overweight | - |
| October 4th 2024 | Wells Fargo | Initiation | Overweight | $17 |
| September 5th 2024 | Jefferies | Initiation | Buy | $9 |
Earnings History & Surprises
ATYRBeat Rate
57%
Last 14 quarters
Avg Surprise
+3.9%
EPS vs Estimate
Beats / Misses
8/6
Last 12 quarters
Latest EPS
$-0.26
Q4 2025
EPS Surprise History
Q1 24
-4.2%
$-0.25vs$-0.24
Q2 24
+4.2%
$-0.23vs$-0.24
Q3 24
-4.5%
$-0.23vs$-0.22
Q4 24
-4.5%
$-0.23vs$-0.22
Q1 25
+21.7%
$-0.18vs$-0.23
Q2 25
+10.5%
$-0.17vs$-0.19
Q3 25
-22.2%
$-0.22vs$-0.18
Q4 25
-30.0%
$-0.26vs$-0.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-0.18 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.20 | $-0.26 | -30.0% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.18 | $-0.22 | -22.2% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-0.19 | $-0.17 | +10.5% | ✓ BEAT |
Q1 2025 | Mar 13, 2025 | $-0.23 | $-0.18 | +21.7% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.22 | $-0.23 | -4.5% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.22 | $-0.23 | -4.5% | ✗ MISS |
Q2 2024 | May 2, 2024 | $-0.24 | $-0.23 | +4.2% | ✓ BEAT |
Q1 2024 | Mar 14, 2024 | $-0.24 | $-0.25 | -4.2% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $-0.23 | $-0.20 | +13.3% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-0.28 | $-0.22 | +19.7% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.35 | $-0.29 | +18.5% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | $-0.48 | $-0.26 | +46.2% | ✓ BEAT |
Q3 2022 | Sep 29, 2022 | $-0.46 | $-0.46 | +0.3% | ✓ BEAT |
Q2 2022 | Jun 29, 2022 | — | $-0.44 | — | — |
Q1 2022 | Mar 30, 2022 | $-0.38 | $-0.44 | -14.4% | ✗ MISS |
Q4 2021 | Dec 30, 2021 | — | $-0.31 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-0.42 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.64 | — | — |
Latest News
RBC Capital Maintains Sector Perform on aTyr Pharma, Lowers Price Target to $1
➖ NeutralBenzinga•Nov 7, 2025, 07:37 PM
aTyr Pharma Q3 EPS $(0.26) Misses $(0.18) Estimate
📉 NegativeBenzinga•Nov 6, 2025, 10:00 PM
aTyr Pharma Highlights Trial Results For Efzofitimod, Aiming To Ease Fatigue And Steroid Use In Pulmonary Sarcoidosis
📈 PositiveBenzinga•Sep 30, 2025, 09:32 AM
Wells Fargo Downgrades aTyr Pharma to Equal-Weight, Lowers Price Target to $1
📉 NegativeBenzinga•Sep 16, 2025, 01:14 PM
RBC Capital Downgrades aTyr Pharma to Sector Perform, Lowers Price Target to $1.5
📉 NegativeBenzinga•Sep 16, 2025, 01:12 PM
HC Wainwright & Co. Downgrades aTyr Pharma to Neutral
📉 NegativeBenzinga•Sep 15, 2025, 06:36 PM
aTyr Pharma stock tanks after missing main goal in lung disease study
📉 NegativeSeeking Alpha•Sep 15, 2025, 01:20 PM
aTyr Pharma shares are trading lower after the company announced topline results from its Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint.
📉 NegativeBenzinga•Sep 15, 2025, 01:10 PM
Trading Halt: Halt status updated at 7:45:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Sep 15, 2025, 11:45 AM
aTyr Pharma Announced Topline Results From The Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis, The Study Did Not Meet Its Primary Endpoint
📉 NegativeBenzinga•Sep 15, 2025, 11:32 AM
Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Sep 15, 2025, 11:25 AM
aTyr Pharma shares are trading higher after Cantor Fitzgerald issued a Buy rating on the stock.
📈 PositiveBenzinga•Sep 12, 2025, 05:27 PM
Jefferies Maintains Buy on aTyr Pharma, Raises Price Target to $17
📈 PositiveBenzinga•Aug 22, 2025, 05:40 PM
Frequently Asked Questions about ATYR
What is ATYR's current stock price?
aTyr Pharma, Inc. (ATYR) is currently trading at $0.75 per share. The stock has moved +6.67% today.
What is the analyst price target for ATYR?
The average analyst price target for ATYR is $5.13, based on 1 analyst.
What sector is aTyr Pharma, Inc. in?
aTyr Pharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ATYR's market cap?
aTyr Pharma, Inc. has a market capitalization of $0.07 billion, making it a small-cap company.
Does ATYR pay dividends?
No, aTyr Pharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACRV
Acrivon Therapeutics, Inc. Common Stock
$2.16
Mkt Cap: $0.1B
ALXO
ALX Oncology Holdings Inc.
$1.45
Mkt Cap: $0.1B
CAMP
CAMP4 Therapeutics Corporation
$6.38
Mkt Cap: $0.1B
DTIL
Precision BioSciences, Inc.
$4.49
Mkt Cap: $0.1B
HYFT
MindWalk Holdings Corp.
$1.67
Mkt Cap: $0.1B
MGX
Metagenomi, Inc. Common Stock
$1.76
Mkt Cap: $0.1B
QNCX
Quince Therapeutics, Inc.
$3.57
Mkt Cap: $0.2B
RLMD
Relmada Therapeutics, Inc.
$4.35
Mkt Cap: $0.3B
RPTX
Repare Therapeutics Inc.
$2.14
Mkt Cap: $0.1B
UNCY
Unicycive Therapeutics, Inc.
$5.56
Mkt Cap: $0.1B
Explore stocks similar to ATYR for comparison